CollPlant Biotechnologies Ltd revenue by segment CLGN

Annual Quarterly

CollPlant Biotechnologies Ltd splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Revenues From Milestones at $2.0 million, 84% of the total.

USD in millions. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
Revenue
2
1
11
0
16
6
2
5
0
Revenues From Milestones
2
share 84.4%
—
10
share 91.2%
—
14
share 89.5%
—
—
—
—
Revenues From Sales Of Goods
0
-28.0%
share 15.6%
1
-46.3%
share 100.0%
1
+220.7%
share 8.8%
0
-81.3%
share 100.0%
2
share 10.2%
—
—
—
—
Revenues From Rendering Of Services
—
—
—
—
0
share 0.3%
—
—
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.

Company profile

Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Listed as
CLGN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Israel
Headquarters
Rehovot, Israel
SEC filer status
Non-accelerated filer
SEC CIK
1631487
Former names
CollPlant Biotechnologies Ltd. (until Jun 20, 2019); CollPlant Holdings Ltd. (until Jun 6, 2019)

Other Orthopedic, Prosthetic & Surgical Appliances & Supplies companies

All 29 Orthopedic, Prosthetic & Surgical Appliances & Supplies companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.